RE:RE:Merck USA (MSD) acquires Phase 2 biotech for US$ 10.8 Bln.Merck's acquisition of Phase 2 biotech company Prometheus Biosciences is another example of Big Pharma's intent on purchasing pre-Phase 3 biotech companies i an effort to control the design of the Phase 3 registration study and as a way to manouver around the FTC's anti-competition actions, that have been fully discussed on this message board.
Refer to FTC's negative ruling on the US$28 Billion Amgen/Horizon acquisition which will impact the potential US$43 Billion acquisition of Seagen by Pfizer.
This places ONCY in a very good position since the FTC is not interested in such an acquisition of ONCY, as demonstrated by the approval of Merck's acquisition of Prometheus Biosciences.